A Wildly Underappreciated Point: Overpaying for Infusions Means Overpaying for Stop-Loss Coverage, With Jake Velie and Keith Hartman, RPh

6 snips

Sep 23, 2026

Jake Velie, a healthcare executive and consultant with health plan expertise, joins pharmacist Keith Hartman to unpack the hidden costs of infusion care. They explore opaque J- and Q-codes, site-of-care decisions, and how overpaying can drive stop-loss premiums, lasering, and lost access to self-funding. They also discuss clinical oversight, member incentives, and proactive intervention.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

J-Codes Hide The Real Cost Of Infusions

J-code and Q-code opacity hides drug acquisition, administration, and site-of-care pricing from plan sponsors.
The same therapy can carry dramatically different markups depending on where treatment occurs.

ADVICE

Put Clinical Judgment Before Site-of-Care Steering

Use clinicians to review treatment plans, drug combinations, and clinical notes before steering patients.
Clinical expertise determines whether care can move from hospital buy-and-bill to an ambulatory center or home.

ADVICE

Match Infusion Sites To Drug Risk

Match each infusion site to the drug’s volatility, patient experience, and emergency-response requirements.
Home care is not automatically appropriate; inexperienced administration can make reactions dangerous.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

The Hidden Link Between Expensive Infusions and Rising Stop-Loss Renewal Premiums. Episode 530.

When an infusion claim lands on a self-insured plan's high-cost claims report, it's tempting to treat the price tag as fixed — but the exact same infusion drug can cost 10 times more depending on where a member receives it, and every expensive claim that breaches a stop-loss attachment point can push next year's premium higher or get that member's claim lasered off coverage entirely. In this episode, Stacey Richter talks with Jake Velie, founder, chairman, and CEO of National Integrative Health (NIH), and Keith Hartman, RPh, NIH's chief strategy officer, about the direct — not dotted — line between overpaying for infusions and overpaying for stop-loss coverage, and the four pillars plan sponsors need to actually pull off site-of-care optimization.

WHAT YOU'LL LEARN

✅ Why there's a direct, not dotted, line between expensive infusion claims and rising stop-loss renewal premiums — and how breaching an attachment point can get a claim lasered off coverage

✅ How the opacity of J-codes and Q-codes on the medical benefit hides how much margin is built into an infusion's billed cost, unlike the more visible pharmacy-benefit claims data

✅ Why the exact same infusion drug can cost 10 times more depending on where a member receives it

✅ The four pillars of a real site-of-care optimization program: deep clinical oversight, proactive pre-cert intervention, plan design and financial incentives, and member/influencer engagement

✅ Why a vague "denied" fax in the pre-cert process leaves prescribing clinicians in the dark and can sabotage a site-of-care redirect before it starts

✅ How home infusion can be used as a site-of-care option even when an anticompetitive hospital contract otherwise restricts steering

WHY THIS MATTERS

Stop-loss coverage is usually a self-insured plan's single biggest expense, yet Stacey Richter points out that the typical reaction to an expensive infusion claim is to treat it like an unalterable fate. The same infusion can cost 10 times more depending on where a member gets it, and every claim that breaches a stop-loss attachment point pushes premiums higher or risks getting the claim excluded from coverage. As medical and pharmacy trend keeps climbing, knowing how to steer members toward lower-cost, clinically appropriate sites of care is becoming a core skill for plan sponsors — not knowing how is turning into a problematic knowledge gap.

MENTIONED IN THIS EPISODE

EP529 with Eric Bricker, MD: Apple Podcasts | Spotify | Other Apps

EP370 with Erik Davis and Autumn Yongchu: Apple Podcasts | Spotify | Other Apps

EP468 with Matt McQuide: Apple Podcasts | Spotify | Other Apps

Website: National Integrative Health

EP501 with Ivana Krajcinovic, PhD: Apple Podcasts | Spotify | Other Apps

EP508 with Lee Lewis: Apple Podcasts | Spotify | Other Apps

EP480 with Kimberly Carleson: Apple Podcasts | Spotify | Other Apps

EP523 with Suhas Gondi, MD, MBA: Apple Podcasts | Spotify | Other Apps

EP472 with Eric Bricker, MD: Apple Podcasts | Spotify | Other Apps

=== LINKS ===

🔗 Show Notes with all mentioned links: Show Notes

✉️ Enjoy this podcast? Subscribe to the free weekly newsletter

🫙 Support the podcast with a small donation to the Tip Jar

🎤 Follow us on Apple Podcasts

🎤 Follow us on Spotify

📺 Subscribe to our YouTube channel

=== CONNECT WITH THE RHV TEAM ===

✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X

00:00 Introduction to this episode.

02:42 An overview of today's conversation.

05:50 The critical pillars plan sponsors underestimate.

07:44 Today's conversation with Keith and Jake.

10:08 Connecting the dots between infusion therapy costs and stop-loss coverage.

13:44 Why stop-loss carriers are starting cost-containment initiatives themselves.

17:36 The things many plans miss.

18:40 Why some plans miss or underestimate extensive clinical capabilities.

20:39 What does "good" look like, relative to a clinical team?

23:10 What do plan sponsors need to ensure further care fragmentation?

27:05 Why plan design and member financial alignment are so important.

29:44 Why is it important for plan sponsors to have a member and influencer engagement engine?

32:58 What about anti-competitive contracts and ASO resistance?

35:15 What National Integrative Health does.

36:22 Where you can go to learn more about National Integrative Health.